Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis

Expert Opinion on Investigational Drugs

Volumn 22, Issue 10, 2013, Pages 1347-1357

  Worm, Margitta ^a   Patel, Deepan ^b   Creticos, Peter Socrates ^c,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Topstone Research   (Canada)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Geticos Research Group   (United States)

Author keywords

Allergic rhinoconjunctivitis; Asthma; Cat allergy; Cat peptide antigen desensitization

Indexed keywords

ALLERGEN; CAT ALLERGEN; FEXOFENADINE; IMMUNOGLOBULIN E; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ARTICLE; BASOPHIL; BRONCHOSPASM; CONTROLLED STUDY; COUGHING; DESENSITIZATION; DRUG DOSE ESCALATION; DRUG SAFETY; EX VIVO STUDY; HEADACHE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INJECTION SITE REACTION; MAINTENANCE DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MAST CELL; NONHUMAN; PALLIATIVE THERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN CROSS LINKING; REGULATORY T LYMPHOCYTE; RHINOCONJUNCTIVITIS; SUBLINGUAL IMMUNOTHERAPY; UPPER RESPIRATORY TRACT INFECTION;

ALLERGENS; ANIMALS; CATS; CLINICAL TRIALS, PHASE III AS TOPIC; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN E; PEPTIDES; RHINITIS, ALLERGIC, PERENNIAL; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884241859     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.827661     Document Type: Article

References (41)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64
2. Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007;120:1139-45
3. Bousquet PJ, Leynaert B, Neukirch F, et al. Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I. Allergy 2008;63:1301-9
4. Morris DO. Human allergy to environmental pet danders: a public health perspective. Vet Dermatol 2010;21:441-9
5. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;4:CD001186
6. Canonica GW, Bousquet J, Casale T, et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64(Suppl 91):1-59
7. Nouri-Aria KT, Durham SR. Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets 2008;7(4):237-52
8. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009;123(4):735-46
9. Muller U, Akdis CA, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-54
10. Norman PS, Ohman JL, Long AA, et al. Treatment of cat allergy with T-cell rective peptides. Am J Respir Crit Care Med 1996;154:1623-8
11. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Feld 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:47-53
12. Alexander C, Ying S, Kay AB, Larché M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005;35:52-8
13. Alexander C, Tarzi M, Larché M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005;60:1269-74
14. Oldfield WL, Kay AB, Larché M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001;167:1734-9
15. Broide DH. Immunomodulation of allergic disease. Annu Rev Med 2009;60:279-9
16. Valenta R, Ferreira F, Focke-Tejkl M, et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010;28:211-41
17. Focke M, Swoboda I, Marth K, et al. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010;40:385-97
18. Briner TJ, Kuo MC, Keating KM, Rogers BL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993;90:7608-12
19. Wallner BP, Gefter ML. Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy 1994;49:302-8
20. Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T cell epitope containing peptides. Am J. Respir Crit Care Med 1996;154:1623-8
21. Norman PS, Nicodemus CF, Creticos PS, et al. Clinical and Immunologic Effects of Component Peptides in Allervax- Cat. Int Arch Allergy Immunol 1997;113:1-3
22. Creticos PS, Hebert J, Philip G; The Allervax- Ragweed Study Group. Efficacy of Allervax- ragweed in the treatment of ragweed-induced allergy. J Allergy Clin Immunol 1997;99(1 Pt 2):S401; 1631
23. Creticos PS. Peptide Downregulation of the Immune Response. In: Marone G, Austen KF, Holgate ST, Barry Kay A, Lichtenstein LM, editors. Asthma and allergic diseases. Academic Press, Elsevier Ltd; 1998;30:407-15
24. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011;127:89-97
25. Kwok WW, Roti M, Delong JH, et al. Direct ex vivo analysis of allergen-specific CD4+ T cells. J Allergy Clin Immunol 2010;125:1407-9
26. Campbell JD, Buckland KF, McMillan SJ, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009;206:1535-47
27. Day JH, Horak F, Briscoe MP, et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006;6:31-59
28. Salapatek AM, Patel P, Chan K, et al. An environmental exposure chamber -specific rhinoconjunctivitis quality of life questionnaire: the symptoms of seasonal allergic rhinitis correlate with the quality of life of patients with ragweed allergy in the chamber. Allergy 2007;62:118-19
29. Larché M, Patel D, Patel P, et al. Safety and efficacy of Fel d 1 derived peptide immunotherapy in a double-blind, placebo-controlled environmental exposure chamber (EEC) study. Allergy 2012;67(Suppl 96):1-97
30. Hafner R, Patel P, Salapatek AM, et al. FEL d 1 peptide antigen desensitization safety and efficacy in a double-blind, placebo-controlled environmental exposure chamber study. World Allergy Organ J
31. Patel D, Couroux P, Hickey P, et al. Feld 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131:103-9
32. Hafner R, Couroux P, Armstrong K, et al. Two Year Persistent Treatment Effect Achieved After 4 Doses of Cat-Peptide Antigen Desensitization (Cat-PAD) in an Environmental Exposure Chamber (EEC) Model of Cat Allergy. J Allergy Clin Immunol 2013;131:AB147
33. Hafner RP, Couroux P, Armstrong K, et al. Total Nasal Symptom Scores are reduced in an EEC model of cat allergy two years after administration of 4 doses of Cat-PAD. Available from: http://www.sessionplan.com/EAACI-WAO2013/Abstract 1887
34. Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997;27:860-7
35. Patel D, Bernstein DL, Plunkett G, et al. Tolerability and efficacy of sublingual immunotherapy in cat allergic subjects studies in an environmental exposure chamber. Ann Allergy Asthma Immunol 2011;107:A105
36. Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol 2011;820:71-84
37. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908-12
38. Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129:1290-6
39. Berkowitz RB, Braker S, Lutz C, et al. Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis. Ann Allergy Asthma Immunol 2006;96:327-33
40. Haumann B, Powell J, Hafner R. Safety and Tolerability of Fel d 1-Derived Peptide Antigen Desensitization. J Allergy Clin Immunol 2013;131:AB38
41. Powell J, Haumann B, Hafner RP. Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes, demonstrates a favourable tolerability profile in patients with cat-induced rhinoconjunctivitis. Available from: http://www.sessionplan.com/EAACI-WAO2013/Abstract 220